Clinical trials: Bortezomib
Idiopathic Multicentric Castleman's Disease
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- NCT03982771
- Testing
- Bortezomib, Cyclophosphamide, Dexamethason
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma
VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates
Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope for the patients with multiple myeloma.
- Trial name
- NCT00320476
- Testing
- Velcade
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Korean Multiple Myeloma Working Party
Multiple Myeloma
Treatment Optimization in Patients With Untreated Multiple Myeloma
This is a multicenter, randomized, blinded, 2-arm phase IIb trial that will compare the efficacy and safety of Lenalidomide maintenance after Bortezomib/Melphalan/Prednison (VMP) induction to VMP without maintenance (Placebo).
- Trial name
- GERMAIN (NCT02145598)
- Testing
- Lenalidomide
- Where
- 19 sites in Germany
- Volunteers
- 85 people
- Sponsor
- Dr. med. Lars-Olof Muegge
Ovarian Cancer, Primary Peritoneal Cancer
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
The goal of this clinical research study is to find the highest safe dose of PS-341 that can be given with carboplatin chemotherapy as a treatment for patients with ovarian, abdominal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00059618
- Testing
- PS-341 (Bortezomib), Carboplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
T-ALL
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2).
- Trial name
- NCT06648889
- Testing
- Isatuximab
- Where
- 15 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Goethe University
Mantle Cell Lymphoma
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating…
- Trial name
- NCT04626791
- Testing
- Acalabrutinib, Bortezomib, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Malignant Mesothelioma
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00458913
- Testing
- bortezomib, cisplatin
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Diffuse Large B-Cell Lymphoma
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Incorporation of rituximab to conventional chemotherapy (R-CHOP) has revolutionalized the frontline treatment of diffuse large B-cell lymphoma (DLBCL), one of the commonest subtype of lymphoma.
- Trial name
- SGH652 (NCT01226849)
- Testing
- bortezomib, rituximab, ifosphamide, etoposide, carboplatin
- Where
- Singapore
- Volunteers
- 6 people
- Sponsor
- Singapore General Hospital
Amyloidosis, Immunoglobulin Light Chain Deposition
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
This phase II trial studies how well ibrutinib with or without bortezomib and dexamethasone works in treating patients with immunoglobulin light chain amyloidosis that has come back after a period of improvement or that does not…
- Trial name
- NCT03130348
- Testing
- Bortezomib, Dexamethasone, Ibrutinib
- Sponsor
- Mayo Clinic
Relapsed and/or Refractory Multiple Myeloma
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in…
- Trial name
- NCT04392648
- Testing
- TAK-573, Pomalidomide, Bortezomib
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Multiple Myeloma
Clarithromycin in Multiple Myeloma Induction Therapy
This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.
- Trial name
- CLAIM (NCT02573935)
- Testing
- Clarithromycin, VCD induction therapy
- Where
- 7 sites in Denmark
- Volunteers
- 58 people
- Sponsor
- Henrik Gregersen
Myeloma
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
A real-world prospective registry study for patients with newly diagnosed multiple myeloma (NDMM) has been conducted at the First Affiliated Hospital of Soochow University since August 2018.
- Trial name
- NCT07206810
- Testing
- Bortezomib, Lenalidomide, and Dexamethasone
- Where
- China
- Volunteers
- 419 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past.
- Trial name
- NCT01602224
- Testing
- Dexamethasone, Bortezomib, Tabalumab
- Where
- 57 sites in United States, Brazil and 13 more
- Volunteers
- 220 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
Given the disappointing results with routine ASCT in t(4;14) patients, we propose this open label phase II study of bortezomib along with dexamethasone and pegylated liposomal doxorubicin (Doxil/Caelyx), referred to as the DBd…
- Trial name
- NCT00570180
- Testing
- Bortezomib
- Where
- 7 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Relapsed and/or refractorY Multiple Myeloma
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
In Korea, VMP is most commonly used as frontline treatment in patients with newly diagnosed MM who were ineligible for high-dose therapy.
- Trial name
- PORYOU (NCT03242460)
- Testing
- Pomalidomide 4 MG, Dexamethasone 20mg, Cyclophosphamide 400mg
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Kosin University Gospel Hospital
Multiple Myeloma
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
- Trial name
- NCT01720043
- Testing
- Velcade
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of bortezomib and sorafenib tosylate when given together with decitabine in treating patients with acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT01861314
- Testing
- Bortezomib, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy-induced Peripheral Neuropathy
Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?
Investigation of which patients treated with bortezomib that have increased risk of developing peripheral neuropathy.
- Trial name
- NFL-BIOPAIN (NCT05781425)
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Multiple Myeloma
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of…
- Trial name
- iMMagine-3 (NCT06413498)
- Testing
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 452 people
- Sponsor
- Kite, A Gilead Company